Skip to main content
Top
Published in: Journal of General Internal Medicine 1/2017

01-01-2017 | Original Research

A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians

Authors: Oni J. Blackstock, MD, MHS, Brent A. Moore, PhD, Gail V. Berkenblit, MD, PhD, Sarah K. Calabrese, PhD, Chinazo O. Cunningham, MD, MS, David A. Fiellin, MD, Viraj V. Patel, MD, MPH, Karran A. Phillips, MD, Jeanette M. Tetrault, MD, Minesh Shah, MD, E. Jennifer Edelman, MD, MHS

Published in: Journal of General Internal Medicine | Issue 1/2017

Login to get access

Abstract

Background

Among health care providers, prescription of HIV pre-exposure prophylaxis (PrEP) has been low. Little is known specifically about primary care physicians (PCPs) with regard to PrEP awareness and adoption (i.e., prescription or referral), and factors associated with adoption.

Objective

To assess PrEP awareness, PrEP adoption, and factors associated with adoption among PCPs.

Design

Cross-sectional online survey conducted in April and May 2015.

Respondents

Members of a national professional organization for academic primary care physicians (n = 266).

Main Measures

PrEP awareness, PrEP adoption (ever prescribed or referred a patient for PrEP [yes/no]), provider and practice characteristics, and self-rated knowledge, attitudes, and beliefs associated with adoption.

Key Results

The survey response rate was 8.6 % (266/2093). Ninety-three percent of respondents reported prior awareness of PrEP. Of these, 34.9 % reported PrEP adoption. In multivariable analysis of provider and practice characteristics, compared with non-adopters, adopters were more likely to provide care to more than 50 HIV-positive patients (vs. 0, aOR = 6.82, 95 % CI 2.06–22.52). Compared with non-adopters, adopters were also more likely to report excellent, very good, or good self-rated PrEP knowledge (15.1 %, 33.7 %, 30.2 % vs. 2.5 %, 18.1 %, 23.8 %, respectively; p < 0.001) and to perceive PrEP as extremely safe (35.1 % vs. 10.7 %; p = 0.002). Compared with non-adopters, adopters were less likely to perceive PrEP as being moderately likely to increase risk behaviors (“risk compensation”) (12.8 % vs. 28.8 %, p = 0.02).

Conclusions

While most respondents were aware of PrEP, only one-third of PrEP-aware PCPs reported adoption. Adopters were more likely to have experience providing HIV care and to perceive PrEP as extremely safe, and were less likely to perceive PrEP use as leading to risk compensation. To enhance PCP adoption of PrEP, educational efforts targeting PCPs without HIV care experience should be considered, as well as training those with HIV care experience to be PrEP “clinical champions”. Concerns about safety and risk compensation must also be addressed.
Appendix
Available only for authorised users
Literature
3.
4.
go back to reference Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.CrossRefPubMed Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.CrossRefPubMed
5.
6.
go back to reference Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS. 2016;11:18–26.CrossRefPubMedPubMedCentral Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS. 2016;11:18–26.CrossRefPubMedPubMedCentral
7.
8.
go back to reference Grant R, Mulligan K, McMahan V, Liu AY, Guanira J, Chariyalertsak S, Bekker L, Schechter M, Veloso VG, Glidden DV. Recovery of Bone Mineral Density After Stopping Oral HIV Preexposure Prophylaxis. Boston, MA: Conference on Retroviruses and Opportunistic Infections; 2016. Grant R, Mulligan K, McMahan V, Liu AY, Guanira J, Chariyalertsak S, Bekker L, Schechter M, Veloso VG, Glidden DV. Recovery of Bone Mineral Density After Stopping Oral HIV Preexposure Prophylaxis. Boston, MA: Conference on Retroviruses and Opportunistic Infections; 2016.
9.
go back to reference Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1291–5.CrossRefPubMed Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1291–5.CrossRefPubMed
10.
go back to reference Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings MK. FTC/TDF (Truvada) for HIV Pre-Exposure Prophylaxis (PrEP) Utilization in the United States: 2012–2015. AIDS 2016 Durban, South Africa; 2016. Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings MK. FTC/TDF (Truvada) for HIV Pre-Exposure Prophylaxis (PrEP) Utilization in the United States: 2012–2015. AIDS 2016 Durban, South Africa; 2016.
11.
go back to reference Castel AD, Feaster DJ, Tang W, et al. Understanding HIV care provider attitudes regarding intentions to prescribe PrEP. J Acquir Immune Defic Syndr. 2015;70:520–8.CrossRefPubMedPubMedCentral Castel AD, Feaster DJ, Tang W, et al. Understanding HIV care provider attitudes regarding intentions to prescribe PrEP. J Acquir Immune Defic Syndr. 2015;70:520–8.CrossRefPubMedPubMedCentral
12.
go back to reference Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58:704–12.CrossRefPubMed Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58:704–12.CrossRefPubMed
13.
go back to reference Krakower DS, Oldenburg CE, Mitty JA, et al. Knowledge, beliefs and practices regarding antiretroviral medications for HIV prevention: results from a survey of healthcare providers in New England. PLoS ONE. 2015;10:e0132398.CrossRefPubMedPubMedCentral Krakower DS, Oldenburg CE, Mitty JA, et al. Knowledge, beliefs and practices regarding antiretroviral medications for HIV prevention: results from a survey of healthcare providers in New England. PLoS ONE. 2015;10:e0132398.CrossRefPubMedPubMedCentral
14.
go back to reference Sharma M, Wilton J, Senn H, Fowler S, Tan DH. Preparing for PrEP: perceptions and readiness of Canadian physicians for the implementation of HIV pre-exposure prophylaxis. PLoS ONE. 2014;9:e105283.CrossRefPubMedPubMedCentral Sharma M, Wilton J, Senn H, Fowler S, Tan DH. Preparing for PrEP: perceptions and readiness of Canadian physicians for the implementation of HIV pre-exposure prophylaxis. PLoS ONE. 2014;9:e105283.CrossRefPubMedPubMedCentral
15.
go back to reference Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDs. 2013;27:553–9.CrossRefPubMed Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDs. 2013;27:553–9.CrossRefPubMed
16.
go back to reference White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDs. 2012;26:395–405.PubMedPubMedCentral White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDs. 2012;26:395–405.PubMedPubMedCentral
17.
go back to reference Smith DK, Mendoza MC, Stryker JE, Rose CE. PrEP awareness and attitudes in a national survey of primary care clinicians in the United States, 2009–2015. PLoS ONE. 2016;11:e0156592.CrossRefPubMedPubMedCentral Smith DK, Mendoza MC, Stryker JE, Rose CE. PrEP awareness and attitudes in a national survey of primary care clinicians in the United States, 2009–2015. PLoS ONE. 2016;11:e0156592.CrossRefPubMedPubMedCentral
18.
go back to reference Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.CrossRefPubMedPubMedCentral Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.CrossRefPubMedPubMedCentral
19.
go back to reference Artenie AA, Jutras-Aswad D, Roy E, et al. Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement. J Viral Hepat. 2015;22:792–9.CrossRefPubMed Artenie AA, Jutras-Aswad D, Roy E, et al. Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement. J Viral Hepat. 2015;22:792–9.CrossRefPubMed
20.
go back to reference Brownson RC, Colditz G, Proctor EK. Dissemination and Implementation Research in Health: Translating Science to Practice. New York: Oxford University Press; 2012.CrossRef Brownson RC, Colditz G, Proctor EK. Dissemination and Implementation Research in Health: Translating Science to Practice. New York: Oxford University Press; 2012.CrossRef
21.
go back to reference Krakower DS, Beekmann SE, Polgreen PM, Mayer KH. Diffusion of newer HIV prevention innovations: variable practices of frontline infectious diseases physicians. Clin Infect Dis. 2016;62:99–105.CrossRefPubMed Krakower DS, Beekmann SE, Polgreen PM, Mayer KH. Diffusion of newer HIV prevention innovations: variable practices of frontline infectious diseases physicians. Clin Infect Dis. 2016;62:99–105.CrossRefPubMed
22.
go back to reference Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18:1712–21.CrossRefPubMedPubMedCentral Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18:1712–21.CrossRefPubMedPubMedCentral
23.
go back to reference Puro V, Palummieri A, De Carli G, Piselli P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis. 2013;13:217.CrossRefPubMedPubMedCentral Puro V, Palummieri A, De Carli G, Piselli P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis. 2013;13:217.CrossRefPubMedPubMedCentral
24.
go back to reference Adams LM, Balderson BH. HIV providers’ likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. AIDS Care. 2016;28(9):1154-8. Adams LM, Balderson BH. HIV providers’ likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. AIDS Care. 2016;28(9):1154-8.
25.
go back to reference Hoffman S, Guidry JA, Collier KL, et al. A clinical home for preexposure prophylaxis: diverse health care providers’ perspectives on the “purview paradox”. J Int Assoc Providers AIDS Care. 2016;15:59–65.CrossRef Hoffman S, Guidry JA, Collier KL, et al. A clinical home for preexposure prophylaxis: diverse health care providers’ perspectives on the “purview paradox”. J Int Assoc Providers AIDS Care. 2016;15:59–65.CrossRef
26.
go back to reference Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE. 2012;7:e40603.CrossRefPubMedPubMedCentral Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE. 2012;7:e40603.CrossRefPubMedPubMedCentral
27.
go back to reference Tripathi A, Ogbuanu C, Monger M, Gibson JJ, Duffus WA. Preexposure prophylaxis for HIV infection: healthcare providers’ knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J. 2012;105:199–206.CrossRefPubMed Tripathi A, Ogbuanu C, Monger M, Gibson JJ, Duffus WA. Preexposure prophylaxis for HIV infection: healthcare providers’ knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J. 2012;105:199–206.CrossRefPubMed
28.
go back to reference Blumenthal J, Jain S, Krakower D, et al. Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19:802–10.CrossRefPubMedPubMedCentral Blumenthal J, Jain S, Krakower D, et al. Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19:802–10.CrossRefPubMedPubMedCentral
29.
go back to reference Mimiaga MJ, White JM, Krakower DS, Biello KB, Mayer KH. Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. AIDS Care. 2014;26:684–93.CrossRefPubMed Mimiaga MJ, White JM, Krakower DS, Biello KB, Mayer KH. Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. AIDS Care. 2014;26:684–93.CrossRefPubMed
30.
go back to reference Desai M, Gafos M, Dolling D, McCormack S, Nardone A, PROUD Study. Healthcare providers’ knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. HIV Med. 2016;17:133–42.CrossRefPubMed Desai M, Gafos M, Dolling D, McCormack S, Nardone A, PROUD Study. Healthcare providers’ knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. HIV Med. 2016;17:133–42.CrossRefPubMed
31.
go back to reference Tang EC, Sobieszczyk ME, Shu E, Gonzales P, Sanchez J, Lama JR. Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru. AIDS Res Hum Retrovir. 2014;30:416–24.CrossRefPubMedPubMedCentral Tang EC, Sobieszczyk ME, Shu E, Gonzales P, Sanchez J, Lama JR. Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru. AIDS Res Hum Retrovir. 2014;30:416–24.CrossRefPubMedPubMedCentral
32.
go back to reference Seidman D, Carlson K, Weber S, Witt J, Kelly PJ. United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: a national survey. Contraception. 2016;93:463–9.CrossRefPubMed Seidman D, Carlson K, Weber S, Witt J, Kelly PJ. United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: a national survey. Contraception. 2016;93:463–9.CrossRefPubMed
33.
go back to reference Lum PJ, Little S, Botsko M, et al. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S91–7.CrossRefPubMed Lum PJ, Little S, Botsko M, et al. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S91–7.CrossRefPubMed
34.
go back to reference Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health. 2013;103:1457–67.CrossRefPubMedPubMedCentral Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health. 2013;103:1457–67.CrossRefPubMedPubMedCentral
36.
go back to reference Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS ONE. 2013;8:e81997.CrossRefPubMedPubMedCentral Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS ONE. 2013;8:e81997.CrossRefPubMedPubMedCentral
37.
go back to reference Mugwanya KK, Donnell D, Celum C, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13:1021–8.CrossRefPubMedPubMedCentral Mugwanya KK, Donnell D, Celum C, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13:1021–8.CrossRefPubMedPubMedCentral
38.
go back to reference McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60.CrossRefPubMedPubMedCentral McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60.CrossRefPubMedPubMedCentral
39.
go back to reference Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61:1601–3.CrossRefPubMedPubMedCentral Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61:1601–3.CrossRefPubMedPubMedCentral
40.
go back to reference Dykema J, Stevenson J, Day B, Sellers SL, Bonham VL. Effects of incentives and prenotification on response rates and costs in a national web survey of physicians. Eval Health Prof. 2011;34:434–47.CrossRefPubMedPubMedCentral Dykema J, Stevenson J, Day B, Sellers SL, Bonham VL. Effects of incentives and prenotification on response rates and costs in a national web survey of physicians. Eval Health Prof. 2011;34:434–47.CrossRefPubMedPubMedCentral
41.
go back to reference Klabunde CN, Willis GB, McLeod CC, et al. Improving the quality of surveys of physicians and medical groups: a research agenda. Eval Health Prof. 2012;35:477–506.CrossRefPubMed Klabunde CN, Willis GB, McLeod CC, et al. Improving the quality of surveys of physicians and medical groups: a research agenda. Eval Health Prof. 2012;35:477–506.CrossRefPubMed
Metadata
Title
A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians
Authors
Oni J. Blackstock, MD, MHS
Brent A. Moore, PhD
Gail V. Berkenblit, MD, PhD
Sarah K. Calabrese, PhD
Chinazo O. Cunningham, MD, MS
David A. Fiellin, MD
Viraj V. Patel, MD, MPH
Karran A. Phillips, MD
Jeanette M. Tetrault, MD
Minesh Shah, MD
E. Jennifer Edelman, MD, MHS
Publication date
01-01-2017
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 1/2017
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-016-3903-z

Other articles of this Issue 1/2017

Journal of General Internal Medicine 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.